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Background: Mucopolysaccharidosis IVA (MPS IVA) is a rare lysosomal storage disorder caused by
N-acetylgalactosamine-6-sulfatase deficiency, which catalyzes a step in the catabolism of glycosaminoglycans,
keratan sulfate and chondroitin-6-sulfate. This disease has a variable age of onset and rate of progression.
Methods: A retrospective analysis of medical records of 24 patients with MPS IVA (11 males, 13 females; current
mean age ± SD, 12.6 ± 6.6 years; age range, 1.4-29.4 years) seen at 6 medical centers in Taiwan from January
1996 through June 2013 was performed.
Results: Mean ages of onset of symptoms and confirmed diagnosis were 2.0 ± 1.6 and 5.7 ± 4.5 years,
respectively. The most prevalent clinical manifestations were kyphosis (100%), pectus carinatum (96%), abnormal
gait (93%), striking short trunk dwarfism (92%), genu valgum (92%), and valvular heart disease (91%). Eight
patients (33%) experienced at least one surgical procedure with the most common being ear tube insertion
(25%), adenoidectomy (17%), tonsillectomy (13%), supraglottoplasty (13%), spinal decompression (13%), and
spinal fusion (13%). The most prevalent cardiac valve abnormalities were aortic stenosis (45%) and mitral
regurgitation (45%). At the time of the study, 8 out of 24 patients (33%) have died at the mean age of 17.2 ±
7.7 years.
Conclusions: An understanding of the natural history involved in MPS IVA may allow early diagnosis of the
disease. All affected Taiwanese patients experienced significant functional limitations. Adequate evaluations and
timely management may improve clinical outcomes and quality of life.
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Mucopolysaccharidosis IVA (MPS IVA; OMIM 253000,
Morquio A disease) is an autosomal recessive disorder
caused by a deficiency of the lysosomal enzyme N-acet-
ylgalactosamine-6-sulfatase (GALNS, EC 3.1.6.4), which
catalyzes a step in the catabolism of glycosaminoglycans
(GAGs), keratan sulfate (KS) and chondroitin-6-sulfate
(C6S). It leads to accumulation of the KS and C6S,
mainly in bone and cornea, causing a systemic skeletal* Correspondence: zsplin14@gmail.com
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unless otherwise stated.dysplasia [1,2]. MPS IVA has a variable age of onset and
rate of progression. Common presenting features include
elevation of urinary and blood KS, short stature, odontoid
hypoplasia, pectus carinatum, kyphosis, scoliosis, genu val-
gum, coxa valga, flaring of the lower ribs, hypermobile
joints, corneal clouding, valvular heart disease, hearing loss,
hepatomegaly, pulmonary compromise, coarse face, widely
spaced teeth, and frequent caries; however, there is no cen-
tral nervous system impairment. Odontoid hypoplasia is
the most critical skeletal feature in MPS IVA patients,
which in combination with ligamentous laxity and extra-
dural GAG deposition, results in atlantoaxial subluxation,
cervical myelopathy, paralysis, or even death.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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not survive beyond the third decade of life primarily
due to cervical instability or pulmonary compromise,
whereas those patients with an attenuated form may sur-
vive over 70 years [3,4]. There has been no specific treat-
ment for MPS IVA, and care has been palliative. Enzyme
replacement therapy (ERT) has emerged as a potential
treatment for MPS IVA [5].
The incidence of MPS IVA differs among different
populations; reported rates range from 1 in 76,000 live
births in Northern Ireland to 1 in 640,000 live births in
western Australia [6,7]. In Taiwan, the incidence of MPS
IVA is approximately 1 in 300,000 live births [8]. The con-
cept of the founder effect may account for the discrepancy
of the incidence in different ethnic populations.
There are only a handful of reports describing the nat-
ural history of MPS IVA [4,9,10]. The purpose of this
study is to retrospectively collect and analyze the clinical
and laboratory information recorded on the medical
charts of Taiwanese MPS IVA patients, including med-
ical history, clinical manifestations and assessments,
diagnosis, and symptomatic management.
Patients and methods
A retrospective study was performed for patients diagnosed
with MPS IVA seen from January 1996 to June 2013 in six
medical centers in Taiwan, including Mackay Memorial
Hospital, Kaohsiung Veterans General Hospital, Taichung
Veterans General Hospital, China Medical University
Hospital, National Taiwan University Hospital, and Chang
Gung Children’s Hospital. The diagnosis of MPS IVA was
confirmed by leukocyte GALNS activity assay and/or two-
dimensional electrophoresis of urinary GAGs [11]. Infor-
mation on 24 patients (11 males and 13 females; mean age,
12.6 ± 6.6 years; age range, 1.4-29.4 years) was collected. Pa-
tients’ charts were reviewed for medical history, clinical
manifestations and assessments, and laboratory studies.
Findings on physical examinations were obtained from phy-
sicians’ records on the outpatient clinic or during admis-
sion. Each patient’s demographic information, including
gender, age at onset of symptoms, age at confirmed diagno-
sis, age at and cause of death (if patient died), laboratory re-
sults, height, weight, body mass index (BMI), ambulatory
status at the time of the latest medical records, physical
examinations, and surgical interventions (if any) were re-
corded as applicable. Any available results of the following
examinations were also collected, including 6-minute walk
test (6-MWT), 3-minute stair climb test (3-MSCT), oph-
thalmologic evaluation for visual acuity and slit lamp exam-
inations, electrocardiography (ECG), echocardiography,
pulmonary function tests by spirometry, hearing as-
sessment by pure-tone audiometry, bone mineral dens-
ity (BMD) by dual energy x-ray absorptiometry (DXA),
polysomnography, and other investigations as well asinformation relevant to the course of disease. Kaplan-
Meier survival analyses were performed to calculate
probability of survival. Standard deviation scores (z scores)
for height, weight, and BMI were calculated using standard
growth tables for Taiwanese population [12]. A z score was
derived by subtracting the population mean from each
individual’s raw score and then dividing the difference by
the standard deviation (SD) of the population. Results are
expressed as the mean ± SD unless otherwise indicated.
ECG and echocardiographic examinations were carried out
as previously described [13], and measurements were com-
pared with normal data [14]. For pulmonary function as-
sessment, forced vital capacity (FVC) and forced expiratory
volume in 1 second (FEV1) were evaluated by standard
spirometry techniques according to the American Thoracic
Society guidelines [15-17]. For hearing assessment by pure-
tone audiometry, the degree of hearing loss was classi-
fied by the age independent World Health Organization
(WHO) clinical guidelines [18]. DXA was performed to
assess BMD of the lumbar spine (L1-L4), using the
Hologic QDR 4500 system (Bedford, MA, USA) [19].
Polysomnography was performed according to the
guidelines of the American Thoracic Society. The ob-
structive apnea-hypopnea index (OAHI) was based on
the number of obstructive/mixed apneas and hypopneas
that occurred per hour of total sleep time [15,20]. Writ-
ten informed consent was obtained from a parent for
children and from patients over 18 years. The study was
approved by the ethics committee of Mackay Memorial
Hospital, Taipei, Taiwan.
Statistical analysis
Descriptive statistics, including means and standard de-
viations, were calculated. The relationship between age
and height, weight, and BMI of the 24 patients with
MPS IVA was determined using Pearson’s correlation
coefficient (r), and significance was tested using Fisher’s
r-z transformations. All statistical analyses were per-
formed using SPSS version 11.5 (SPSS Inc., Chicago, IL,
USA), and differences with p < 0.05 were considered sta-
tistically significant.
Results
Table 1 showed the medical history, laboratory data, and
clinical manifestations of 24 patients with MPS IVA in
Taiwan. The mean ± SD ages of onset of symptoms and
confirmed diagnosis were 2.0 ± 1.6 and 5.7 ± 4.5 years,
respectively. The most common initial symptom was ky-
phosis or gibbus (92%, 22/24). The ambulatory status of
these 24 patients was 13 (54%) with walking, 7 (29%)
with wheelchair bound, and 4 (17%) with bedridden. For
11 patients who were able to perform the physical en-
durance tests, the mean ± SD values of 6-MWT and 3-
MSCT were 235.3 ± 125.5 m and 31.0 ± 13.0 stairs/min,










































1 M 1.4 0.5 1 gibbus,
kyphosis
0.03 519.1 −0.54 0.00 0.46 Walking NA NA NA
2 M 2.7 0.5 1.2 kyphosis 0.1 220.4 −2.25 −0.93 −0.42 Walking NA NA NA
3 M 5.3 0.4 1 gibbus 0.04 NA −3.84 −2.54 −1.34 Wheelchair
bound




4 F 5.8 0.3 3.5 pigeon
chest,
gibbus
0.77 NA −3.84 −2.00 1.66 Walking 183.9 37 0.6/0.6
5 F 7.2 2.4 2.5 chest cage
deformity
0.51 445.6 −4.00 −1.56 0.51 Walking 219.3 15 0.2/0.3
6 M 7.3 1 2.5 pigeon
chest
0.3 218.5 −6.96 −1.53 2.64 Walking 225.9 28 0.4/0.4
7 F 7.6 1.7 6.5 pigeon
chest
0.09 191.5 −2.68 −1.28 −0.14 Walking 360 55 0.4/0.4
8 F 7.7 2 8 kyphosis,
chest cage
deformity
0.4 228.5 −5.63 −2.18 0.29 Bedridden NA NA NA 10.1 Unknown




0.5 NA −6.98 −2.39 −0.47 Wheelchair
bound
NA NA NA 10.8 Unknown
10 M 12.1 2.1 9 kyphosis,
pigeon
chest
0.043 251.1 −1.18 −0.78 −0.42 Wheelchair
bound
NA NA 0.6/0.6 19.4 Airway
impairment
11 F 12.6 4 4 kyphosis 0.3 203.6 −4.35 −2.02 −0.85 Walking 125.7 15 1.0/1.0
12 M 13.2 1.5 10 kyphosis,
chest cage
deformity
0.6 332.5 −7.35 −2.94 −1.35 Bedridden NA NA NA 16.8 Unknown
13 F 13.6 3 3.1 kyphosis 0.3 333.6 −11.28 −3.25 0.05 Walking 495.9 48 0.3/0.4
14 M 13.9 4.5 5 kyphosis,
chest cage
deformity
0.3 251.1 −9.20 −2.99 −0.53 Walking 147 24 NA
15 F 14.7 4 4.3 kyphosis,
chest cage
deformity



















Table 1 Medical history, laboratory data and clinical manifestations of 24 patients with MPS IVA in Taiwan (Continued)
16 F 14.8 0.4 0.4 kyphosis,
chest cage
deformity
0.1 179.4 −12.25 −3.49 0.11 Walking 140.7 37 0.3/0.9




0.7 451.3 −10.23 −3.13 −0.15 Bedridden NA NA NA
18 M 15.8 0.6 5 kyphosis 0.5 NA −9.66 −3.24 −1.25 Wheelchair
bound
NA NA 0.5/0.6
19 F 15.8 5.2 6 kyphosis,
chest cage
deformity
0.4 333.6 −12.27 −3.93 0.03 Walking 360 19 0.5/0.4




0.172 222.8 −12.36 -4.06 −0.74 Wheelchair
bound
NA NA NA 20.0 Airway
impairment
21 F 16.8 1 1.5 kyphosis 0.3 NA −10.45 −3.07 0.48 Walking 72.9 27 0.6/1.0
22 F 18.4 4 14 kyphosis,
chest cage
deformity
0.5 NA −10.66 −3.94 −0.66 Wheelchair
bound
NA NA NA 23.1 Unknown
23 M 25.7 0.5 4.5 kyphosis 0.4 118.6 −10.46 −2.96 0.16 Walking 256.5 37 0.5/0.1




0.11 103.6 −11.54 −3.16 0.31 Wheelchair
bound
NA NA NA 30.3 Airway
impairment
Mean 12.6 2.0 5.7 0.3 273.8 −7.51 −2.54 −0.10 235.3 31.0 17.2
SD 6.6 1.6 4.5 0.2 113.6 3.86 1.09 0.91 125.5 13.0 7.7
aNormal value: 5.9-27.8 nmol/h/mg protein.
bNormal values are age dependent: 1-3 years, 20.0-110.5; 3-5 years, 10.7-112.0; >5 years, 10.8-77.5.
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patients had passed away at the mean ± SD age of 17.2 ±
7.7 years (range 6.8-30.3 years). The cause of death was
identified in 4 patients, while 4 patients died without a
definite cause recorded. Figure 1 showed the Kaplan-
Meier Survival Curve for these 24 patients. The survival
probabilities at 5, 10, 15, 20, and 25 years were 100%,
84%, 84%, 45%, and 30%, respectively. Twenty-two pa-
tients (92%) had short stature and 17 (71%) were under-
weight with a z score of < −2. The mean z scores for
height, weight, and BMI at the time of the latest medical
records were −7.51 ± 3.86, -2.54 ± 1.09, and −0.1 ± 0.91,
respectively. Both z scores for height and weight were
negatively correlated with age (r = −0.769 and −0.693,
respectively; p <0.01) (Figure 2). The most prevalent
clinical manifestations were kyphosis (100%), pectus
carinatum (96%), flaring of the lower libs (96%), abnor-
mal gait (93%), striking short trunk dwarfism (height z
score < −2) (92%), genu valgum (92%), and valvular heart
disease (91%) (Figure 3). Eight patients (33%) experi-
enced at least one surgical procedure. The most preva-
lent surgical interventions were ear tube insertion (25%),
adenoidectomy (17%), tonsillectomy (13%), supraglotto-
plasty (13%), spinal decompression (13%), and spinal
fusion (13%) (Figure 4).Slit lamp examination by ophthalmologists
Visual acuity assessment by Snellen Fraction (n = 13) re-
vealed that 9 of the 13 patients (69%) had normal right
eye vision (20/63 or better), and 11 patients (85%) had
normal left eye vision (20/63 or better). Ocular abnor-
malities in the 15 patients assessed included 14 patients
(93%) with corneal clouding, 9 (60%) with astigmatism,Figure 1 Kaplan-Meier Survival Curve for 24 Patients with MPS IVA in5 (33%) with hyperopia, 2 (13%) with myopia, and 1
(7%) with glaucoma.ECG and echocardiography
The most common results from ECGs (n = 17) showed
the presence of sinus arrhythmia (47%), sinus tachycardia
(35%), and right or left axis deviation (18%). Echocardio-
graphic examinations (n = 22) revealed that 20 patients
(91%) had valvular heart disease. Sixteen (73%) and eleven
patients (50%) had valvular regurgitation or stenosis,
respectively. The most prevalent cardiac valve abnor-
malities were aortic stenosis (45%) and mitral regurgi-
tation (45%), followed by tricuspid regurgitation (41%),
aortic regurgitation (32%), mitral stenosis (32%), and
pulmonary regurgitation (9%) (Figure 5). Nine patients
(41%) had a thickened interventricular septum. The ex-
istence of the thickened interventricular septum was
positively correlated with the increasing age (r = 0.690,
p <0.01).
Pulmonary function tests by spirometry
Thirteen patients had spirometric assessment performed
to evaluate pulmonary function. By spirometric classifi-
cation, 11 patients (85%) had small airway disease [mean
forced expiratory flow during the middle half of FVC
(FEF25-75%) < 65%], and 4 (31%) had restrictive lung dis-
ease (FEV1/FVC >0.7 with FVC <80% predicted).
Hearing assessment by pure-tone audiometry
Hearing assessment by pure-tone audiometry was car-
ried out in 9 patients. Mean values of air conduction
(AC) and bone conduction (BC) of the better ear were
47.8 dB and 29.3 dB, respectively (normal hearing AC ≤Taiwan.
Figure 2 Age against standard deviation scores (z scores) for height (a) and weight (b) of 24 patients with MPS IVA. The values of the 2
parameters both decreased with age (p < 0.05). Horizontal lines represent the lower limits of normal.
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(normal hearing air-bone gap < 15 dB). According to the
WHO classification, 6 patients (67%) had various de-
grees of hearing loss (AC > 25 dB) with moderate (AC
41–60 dB) in 3, severe (AC 61–80 dB) in 2, and pro-
found (AC ≥ 81 dB) in 1 patient. Three patients were
classified with mixed type hearing loss, 1 with pure con-
ductive type, 1 with pure sensorineural type, and 1
undefined.
BMD assessment by DXA
Eight patients had DXA to access BMD. After correction
for height-for-age z score (HAZ) as previously described
[19], HAZ adjusted BMD z score was −0.72 ± 1.27. Three
patients (38%) had osteopenia (HAZ adjusted BMD z
score < −1 and ≥ −2) and 1 patient (13%) had osteoporosis
(HAZ adjusted BMD z score < −2).
Polysomnography
Overnight polysomnographic findings were available in 3
patients. They all had some degree of obstructive sleepFigure 3 Clinical features of 24 patients with MPS IVA in Taiwan.apnea with mild (OAHI 1.5-5) in 1, and moderate
(OAHI 5–10) in 2.
Discussion
This is the first report to describe the natural history
and clinical features of patients with MPS IVA in a sin-
gle population. As far as we are aware, these were the
only patients in Taiwan with confirmed diagnosis with
MPS IVA at the time of this study. Accurate knowledge
of the natural course of the disease will assist in evalu-
ation of clinical and biomarker endpoints for clinical tri-
als and to judge disease progression and therapeutic
effects. The natural course and clinical manifestations of
this disorder have been reported by the International
Morquio A Registry and the Morquio A Clinical Assess-
ment Program (MorCAP) [4,10]. Although the number
of enrolled patients in these studies was as large as 326
and 325 subjects from 42 and 10 countries, respectively,
the reports were collected from different ethnic popula-
tions, as well as analyzed altogether. Our results showed
that Taiwanese patients with MPS IVA manifest a broad
Figure 4 Types of surgical interventions for 24 patients with MPS IVA in Taiwan.
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dicating the clinical heterogeneity of the disease.
Information characterizing cause of death in MPS IVA
is limited in the literature. In the report of Hunter Out-
come Survey (HOS) [21], 46% (59/129) mortality was
caused by airway impairment. Shih et al. [22] described
that there were significant airway changes in the shape
of the vocal cords and trachea in patients with MPS,
which may be due to abnormal submucosal storage of
GAG. Hendriksz et al. [23] reported that high mortality
and morbidity rates in patients with severe MPS IVA are
related to the occurrence of cervical myelopathy and dys-
plasia. Thus it was reasonable that 3 out of our 4 patientsFigure 5 Incidence of cardiac valve abnormalities in 22 patients with
mitral regurgitation; MS, mitral stenosis; PR, pulmonary regurgitation; PS, puwho died with a definitive cause were due to airway impair-
ment, and the other was owing to atlantoaxial subluxation
with spinal cord compression.
Montano et al. [4] reported that the mean ages of ini-
tial symptoms and confirmed diagnosis were 2.1 and
4.7 years, respectively, for patients in the International
Morquio A Registry data. We had similar result with the
age of initial symptoms being 2.0 years. However, the
age of confirmed diagnosis in our series was delayed for
1 year (5.7 years).
In Montano’s data, 52% patients underwent surgical
intervention, with the most frequent interventions being
cervical spinal fusion and decompression (51%) and earMPS IVA in Taiwan. AR, aortic regurgitation; AS, aortic stenosis; MR,
lmonary stenosis; TR, tricuspid regurgitation; TS, tricuspid stenosis.
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at least one surgical intervention with 25% being ear
tube insertion, and only 13% undergoing cervical spinal
fusion and decompression. This may be due to the mean
age of patients in Montano’s data being 16.9 years,
whereas mean age in our data was 12.6 years. Due to the
progressive worsening of this disorder, the younger age
of our patients may explain the lower percentage receiv-
ing operations. An alternative thought is that regular
magnetic resonance imaging and prophylactic interven-
tion are not part of clinical management in Taiwan
compared with US, UK and part of Europe. Besides, the
disease awareness of both medical providers and care-
givers for the need for surgical procedures may also play
a pivotal role for the discrepancy between these 2 data
sets.
Short stature is one of the most characteristic features
of MPS IVA. Ninety-two percent of our patients had
striking short stature and 71% weight below normal for
age with a z score of < −2. The mean z scores for height
and weight were −7.51 ± 3.86 and −2.54 ± 1.09, respect-
ively. The older patients had even lower z scores for
height and weight, illustrating the progressive nature of
the disease.
Montano et al. [4] described that 2/3 of their MPS
IVA patients had hypermobility of joints, a unique fea-
ture to Morquio A syndrome caused by metaphyseal
deformities and degradation of connective tissue near
the joint, similar to the 79% reported in our study.
In our study population, 33% had dental caries and
75% had widely spaced teeth, consistent with James et al.
[24] who reported that patients with MPS IVA have in-
creased caries rates and enamel defects comparing with
both patients with other MPS types and the general
population.
Physical endurance measures are important indicators
for evaluating functional impairment in subjects with
progressive diseases [25]. The results of 6-MWT and 3-
MSCT in the MPS IVA population show impairment re-
gardless of age group [10]. In our study, only 11 patients
(46%) were able to perform the physical endurance tests.
The mean 6-MWT distance of 235.3 ± 125.5 m is signifi-
cantly reduced as compared with the normal range of
470–664 m for unaffected children aged 4–16 years, and
500–580 m for healthy adults [26-28]. The mean 3-
MSCT value of 31.0 ± 13.0 stairs/min also revealed a sig-
nificant impairment comparing with the baseline stair
climb rate of 50 ± 29.5 stairs/min in the Phase 2 study
for the MPS VI patients. However, in the Phase 3 study,
rates were significantly lower 30 and 19 on the placebo
and active treatment groups [29].
Danes et al. [30] described that diffuse corneal cloud-
ing is the most common ocular finding in MPS IVA, al-
though it occurs to a lesser extent and is more slowlyprogressive than in other MPS types. Couprie et al. [31]
reported that patients with MPS IV tend to have astig-
matism besides myopia and hyperopia. In our study sub-
jects, 93% had corneal clouding, 60% had astigmatism,
33% had hyperopia, and 13% had myopia in accordance
with referenced findings.
Our findings were consistent with the assertions of previ-
ous underreporting of cardiac involvement in MPS IVA ac-
cording to the findings from the MorCAP population [10].
In our data, ECGs showed 47% had sinus arrhythmia and
35% had sinus tachycardia. Echocardiographic examina-
tions also revealed 91% had valvular heart disease, as well
as 73% and 50% had valvular regurgitation or stenosis, re-
spectively. Nine patients (41%) had thick interventricular
septum. The positive correlation between the presence of
thick interventricular septum and increasing age reinforced
the concept of the progressive nature of cardiac disease.
There are multifactorial etiologies for respiratory func-
tion impairment in patients with MPS IVA, including
upper and lower airway obstruction, chest wall restric-
tion, short stature, skeletal dysplasia, and cervical myel-
opathy. GAG is accumulated throughout the respiratory
system [4]. In our study, we found a high prevalence of
pulmonary function impairment by spirometric classifi-
cation in MPS IVA patients characterized by 85% with
small airway disease and 31% with restrictive lung dis-
ease. However, these percentages determined by compar-
ing to normal standards for height which are
problematic in MPS populations (severe short stature as
well as joint disease makes height difficult to measure).
Thus it would have expected that more than 31% to
have restrictive lung disease.
Patients with MPS IVA experience hearing loss attributed
to multiple causes. Conductive hearing loss is usually sec-
ondary to recurrent upper respiratory tract infection and
serous otitis media, as well as caused by ossicle deformity.
Sensorineural hearing loss may occur due to GAG accumu-
lation. Most patients have a “mixed” hearing loss with the
combination of conductive and sensorineural elements
[10,32]. In our data, 67% patients had hearing loss, and a
half of them could be classified with the mixed type, similar
with those of the previous literature.
Patients with MPS have an increased risk of poor bone
mineralization due to malnutrition, a particularly small
frame, an abnormal gait, and reduction of physical activ-
ities caused by pain, poor health condition, or exercise
intolerance [19]. In our study, according to BMD assess-
ment by DXA, a half of MPS IVA patients had osteope-
nia or osteoporosis.
Sleep-disordered breathing, specifically obstructive
sleep apnea, is a common disorder in patients with MPS
[20]. In our study, only 3 MPS IVA patients had over-
night polysomnographic reports, and all of them had
some degree of obstructive sleep apnea.
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systemic dysfunction, including skeletal, visual, auditory,
cardiovascular, and respiratory systems, which severely
affect patient quality of life by reducing endurance, increas-
ing dependence on caregivers, and limiting participation in
daily activities. As a result, multi-disciplinary approach to
patient care is required once the diagnosis is made.
Limitations
As a retrospective and multicenter study, there is a lack of
complete data for all of our subjects. Assessments per-
formed also varied by institution and treating physician.
Small sample size reflected the rare nature of this genetic
disorder, and the range of age was quite wide, as was the
degree of disease severity. Therefore, studies in larger
cohorts with a longer follow-up are warranted. However,
our experience reflects the problem that clinicians are likely
to encounter when treating patients with MPS IVA, since
each patient presents with a significant variation.
Conclusion
An understanding of the natural history and character-
ization of the clinical impairments involved in MPS IVA
may allow early diagnosis and potentially facilitate better
management of the disease. In our study, all affected
Taiwanese patients experienced significant functional limi-
tations, and regular evaluations and timely management
may improve their quality of life. These findings and the
follow-up data can be used to develop quality of care strat-
egies, as well as to offer guidance for clinical trial outcomes
and diagnostic process for patients with MPS IVA.
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